March 1971

Thiabendazole in Visceral Larva Migrans

Author Affiliations

From St. Jude Children's Research Hospital and the University of Tennessee Medical Units, Memphis.

Am J Dis Child. 1971;121(3):226-229. doi:10.1001/archpedi.1971.02100140092008

Thiabendazole, a broad spectrum anti-helminthic agent, was administered to three children with visceral larva migrans in a dosage of 20 to 50 mg/kg daily for seven to ten days. The children had presented with fever, weight loss, anemia, lymphoadenopathy, hepatosplenomegaly, perihilar infiltrates, leukocytosis, and eosinophilia. This course was repeated after a four-week interval. After thiabendazole therapy, they demonstrated rapid clinical and laboratory improvement, contrasting with the prolonged duration of disease when no therapy is given. There was no evidence of drug-associated toxicity.